WONIK Investment Partners
VC Fund
Seoul, South Korea
WONIK Investment Partners is a VC fund in Seoul focused on Health Care and Biotechnology. Wonik Investment Partners, formerly known as Hanmi Technology Investment Co., Ltd., is a private equity and venture capital firm specializing in investments in incubation, start-up, early and mid-stage companies, growth capital and corporate restructuring. The firm prefers to invest in gaming contents, electronic components, computer,telecommunications equipment, petroleum, energy, machinery and equipment industries. It seeks to exit through an IPO or merger and acquisition. Wonik Investment Partners was established in 1997 and is based in Seoul, South Korea.
- Total investments:
- 81
- Last investment:
- Lead investor:
- 2%
Last updated:
For AI agents: llms.txt
Industries WONIK Investment Partners invests in
Stages WONIK Investment Partners invests in
Countries WONIK Investment Partners invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
3 more contacts available
Round size
- Seed
- $785k–$6.9M
- Series A
- $2.5M–$17M
- Series B
- $1.5M–$19M
Investment Focus
Industry
- Health Care 15 (19%)
- Biotechnology 14 (17%)
- Manufacturing 12 (15%)
- Medical 9 (11%)
- Software 6 (7%)
Stage
- Series B 29 (36%)
- Series A 24 (30%)
- Seed 8 (10%)
- Venture - Series Unknown 8 (10%)
- Series C 7 (9%)
Country
- South Korea 61 (75%)
- United States 2 (2%)
- United Kingdom 2 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Lee Yong -seong
CEO
|
CEO | Total investments: 0 | Find email | |
|
Cho Sung-woo
Director
|
Director | Total investments: 1 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
|
Awexome Ray
|
Awexome Ray is a company that manufactures next-generation X-ray generator. | $5.3M / Series B / Aug 10, 2026 | |
Dentlink
|
Dentlink aims to advance human oral health care by integrating digital technology. | $7.8M / Series B / Jun 23, 2026 | |
XCENA
|
XCENA is a semiconductor company that develops data-centric computing systems designed for AI and large-scale data processing environments. The company builds computational memory technology that combines high-capacity pooled DDR5 memory with near-data processing capabilities, allowing computation to occur closer to where data is stored. Its coreplatform is based on the Compute Express Link (CXL) standard, which enables memory expansion beyond traditional CPU limitations while improving data movement efficiency and reducing latency in data center workloads. XCENA’s architecture is designed to support applications such as artificial intelligence workloads, vector databases, and large-scale analytics by addressing memory bandwidth and capacity constraints. The company provides a hardware-software ecosystem that includes computational memory systems and a full-stack software development kit. This SDK offers APIs, runtime tools, and drivers that allow applications to use computational memory without major changes to existing software architectures while also supporting low-level control for performance optimization.XCENA’s flagship product line includes MX1, a CXL-based computational memory solution that integrates near-data processing engines with memory infrastructure to support AI inference and data-intensive workloads. The platform is designed to improve throughput and scalability in environments where traditional memory architectures become a bottleneck. The company operates in the broader field of AI infrastructure and memory innovation, working with customers such as hyperscalers, telecom providers, and research institutions that manage large-scale computing workloads. Its solutions are intended to improve efficiency in systems handling AI, big data processing, and scientific computing. | $135M / Series B / May 29, 2026 | |
BrainU
|
BrainU is a medical equipment manufacturing company taht developer of medical monitoring device designed to monitor brain activity. BrainU device measures the depth of anaesthesia during surgery by analysing and quantifying the entire EEG, biocompatibility, and applying a hypoallergenic, simple sensor. | $2M / Series A / Mar 31, 2026 | |
Mustbio
|
MustBio is a biotechnology company that leverages multi-antibody technology to develop therapeutics primarily in the field of immuno-oncology. The company was founded in 2021 and is based in Seoul, South Korea. | $23.3M / Series C / Mar 13, 2026 | |
RafiQ Cosmetics
|
RafiQ Cosmetics uses cosmetic raw material technology that eliminates the need to use extracts or wash off plant plant. | $10.7M / Series B / Sep 29, 2025 | |
Nex Eye
|
Nex Eye is an innovative biotechnology firm that offers revolutionary immunotherapy solutions for individuals battling cancer. The company addresses the fundamental reasons behind the failure of immunotherapy, which are influenced by the biology of cancer itself. Utilizing its ON-SMRT® platform based on actual patient data and resistant cancermodels, Nex Eye identifies new immune-evasion targets such as ONCOKINE®. By transforming the approach to tackling immune resistance, the firm is pioneering a new era in cancer therapy by revitalizing the capabilities of the immune system. | $44.2M / Series B / Aug 13, 2025 | |
ROBOS
|
Robos is a hybrid robot system built by evaluating biological object vision data using Lidar Vision and Open CV-based Object Detection. By combining self-developed biomaterial machine vision technology and robot technology, it intends to expand into a company that delivers core services to diverse industrial sites such as manufacturing, food, andmedical. | $18.2M / Series B / Jun 18, 2025 | |
ASWEMAKE
|
ASWEMAKE is a provider of digital transformation management solutions, dedicated to creating a customer experience that makes purchasing daily necessities online as satisfying as buying them in person. By focusing on developing online sales infrastructure within competitive nationwide food ingredient markets and collaborating with local offlinepartners, the company aims to achieve 'Today's Shopping,' where orders made today are delivered the same day throughout the country, leveraging logistics and distribution services. It operates 'Q Market,' an application for same-day delivery from local grocery stores. Q Market serves as an O2O service that links consumers residing within a 3km radius of medium-to-large offline supermarkets, using city center supermarkets as delivery hubs to ensure that orders reach customers' doorsteps on the same day. The company is committed to offering consumers a fresher 'Convenience Premium' (Convenience + Premium) by setting itself apart through the use of logistics warehouses associated with supermarkets, ensuring that the products customers require are delivered as quickly as possible. | $7.4M / Series C / Jun 05, 2025 | |
INTAKE foods
|
INTAKE foods (인테이크푸즈) is a company focused on food content development and food branding, specialized in the innovation of leading food brands. It is focused on brand development, content development and publishing, such as food activities, intake of foods, and a food culture of innovation. | $9.2M / Series C / Apr 01, 2025 | |
| See all 81 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does WONIK Investment Partners invest in?
WONIK Investment Partners invests primarily in Health Care, Biotechnology and Manufacturing startups, most often at Series B and Series A stage. Most of the 81 investments tracked by Shizune back companies in South Korea. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is WONIK Investment Partners's check size?
WONIK Investment Partners typically joins rounds of $785k–$6.9M at Seed, $2.5M–$17M at Series A and $1.5M–$19M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds WONIK Investment Partners participates in.
How do I contact WONIK Investment Partners?
Public channels for WONIK Investment Partners include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at WONIK Investment Partners?
The team at WONIK Investment Partners includes Lee Yong -seong (CEO) and Cho Sung-woo (Director). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
